TTrialPathMatch Me to Trials
← Back to trials
RecruitingGaucher DiseaseCerebroside Lipidosis SyndromeGlucocerebrosidase Deficiency Disease

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

Eligible age

All ages

Accepts

All genders

Locations

38 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives of the Registry are: * To enhance understanding of the variability, progression, identification, and natural history of Gaucher disease, with the ultimate goal of better guiding and assessing therapeutic intervention. * To assist the Gaucher medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care. * To characterize the Gaucher disease population. * To evaluate the long-term effectiveness of imiglucerase and of eliglustat. Gaucher Pregnancy Sub-registry: The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Gaucher disease during pregnancy, regardless of whether they receive disease-specific therapy. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.

Sponsor: Genzyme, a Sanofi Company

You may qualify if…

  • ✓ ICGG Gaucher Registry
  • ✓ All patients with a confirmed diagnosis of Gaucher disease are eligible for inclusion in the Registry. Confirmed diagnosis is defined as a documented β-glucocerebrosidase deficiency and/or mutation in the β-glucocerebrosidase gene.
  • ✓ For all patients, appropriate patient authorization will be obtained.
  • ✓ Gaucher Pregnancy Sub-registry:
  • ✓ be enrolled in the ICGG Gaucher Registry.
  • ✓ be pregnant, or have been pregnant with appropriate medical documentation available.
  • ✓ provide a signed informed consent and authorization form(s) to participate in the Sub-Registry prior to any Sub-Registry-related data collection being performed.

You may not qualify if…

  • ✕ \- No exclusion criteria for participation in the ICGG Gaucher Registry and Sub-registry.

Where it's recruiting

Alabama

Birmingham

Arizona

Phoenix · Tucson

Arkansas

Little Rock

California

Beverly Hills · Los Angeles · Orange · Sacramento …

Colorado

Aurora

Connecticut

New Haven

District of Columbia

Washington D.C.

Florida

Coral Gables · Coral Springs · Jacksonville · Tampa

Georgia

Decatur

Illinois

Chicago

Indiana

Indianapolis

Iowa

Iowa City

Source: ClinicalTrials.gov · NCT00358943 · last updated 2026-11-17

International Collaborative Gaucher Group (ICGG) Gaucher Disease Regis · TrialPath